Key result
Losartan plus enalapril reduces systolic blood pressure ~17% versus losartan alone in hypertensive rats.
Why the study?
It was unknown whether dual renin-angiotensin system blockade induces additional beneficial effects on cardiovascular remodelling compared with monotherapy in renal hypertensive two kidneys-one clip rats.
Does dual RAS blockade with losartan and enalapril improve cardiovascular remodeling compared to monotherapy in renovascular hypertensive rats?
Does dual RAS blockade with losartan and enalapril improve cardiovascular remodeling compared to monotherapy in renovascular hypertensive rats?
Combined ACEi and ARB therapy in renovascular hypertensive rats provides additional blood pressure reduction compared to monotherapy, but does not offer further benefits on cardiovascular remodeling.
OBJECTIVES: Evaluate whether the RAS dual blockade would induce additional beneficial effects on cardiovascular remodelling when compared to monotherapy in renal hypertensive two kidneys-one clip (2K-1C) rats. METHODS: Hypertensive 2K-1C and normotensive (2K) rats were treated for 14 days with submaximal doses of losartan (LOS), enalapril (ENA), losartan plus enalapril (LOS + ENA) or vehicle (water). Blood pressure and some parameters of cardiovascular remodelling were evaluated. RESULTS: Systolic blood pressure (SBP) was higher in 2K-1C (209 ± 3 mm Hg, P < .05) than in 2K (113 ± 1 mm Hg) rats. There was an additional effect in 2K-1C treated with LOS + ENA (153 ± 9 mm Hg) on lowering SBP when compared to LOS (184 ± 12 mm Hg) or ENA (177 ± 9 mm Hg). None of the treatments had effect on SBP in 2K rats. In 2K-1C, cardiomyocyte hypertrophy was reduced by all treatments, although the cardiac hypertrophy indexes remained unchanged. 2K-1C aortas presented medial thickening that was partially reduced by the treatments. Intimal hyperplasia observed in 2K-1C (15.56 ± 0.89 µm vs 8.24 ± 0.80 µm) was reversed by ENA (9.52 ± 0.45 µm) or LOS + ENA (8.17 ± 0.53 µm). Collagen deposition was increased in 2K-1C hearts (1.77 ± 0.16 vs 1.28 ± 0.09) and aortas (8.1 ± 0.6 vs 5.2 ± 0.2). Treatment with LOS reduced (1.12 ± 0.14%) and ENA (0.81 ± 0.11%) or LOS + ENA (0.86 ± 0.11%) additionally diminished collagen only in 2K-1C hearts. CONCLUSIONS: Submaximal doses of ACEi and/or ARB have inhibitory actions on cardiac remodelling and vascular hypertrophy not entirely dependent on their effects on blood pressure normalization in renovascular hypertensive rats. Combined therapy produced additional reduction in blood pressure than monotherapy despite a similar inhibition on cardiovascular remodelling.
No takes yet. Share an insight, caveat, or question.
Corrêa et al. (2020) studied Renovascular hypertension. Losartan plus enalapril (LOS + ENA) vs. Losartan (LOS), enalapril (ENA), or vehicle (water) was evaluated on Systolic blood pressure and cardiovascular remodelling. Combined therapy with losartan and enalapril in hypertensive rats reduced systolic blood pressure to 153 ± 9 mm Hg compared to 184 ± 12 mm Hg with losartan and 177 ± 9 mm Hg with enalapril.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: